Your browser doesn't support javascript.
The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study.
Gerosa, Maria; Schioppo, Tommaso; Argolini, Lorenza Maria; Sciascia, Savino; Ramirez, Giuseppe Alvise; Moroni, Gabriella; Sinico, Renato Alberto; Bonelli, Grazia; Alberici, Federico; Mescia, Federica; Moroni, Luca; Tamborini, Francesco; Miraglia, Paolo; Bellocchi, Chiara; Beretta, Lorenzo; Roccatello, Dario; Dagna, Lorenzo; Bozzolo, Enrica; Caporali, Roberto.
  • Gerosa M; Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy.
  • Schioppo T; ASST Pini CTO, Lupus Clinic, Division of Clinical Rheumatology, 20122 Milan, Italy.
  • Argolini LM; ASST Santi Paolo e Carlo, Medicina Generale I, 20142 Milan, Italy.
  • Sciascia S; ASST Pini CTO, Lupus Clinic, Division of Clinical Rheumatology, 20122 Milan, Italy.
  • Ramirez GA; Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy.
  • Moroni G; Nephrology and Dialysis Unit & CMID (Center of Research of Immunopathology and Rare Diseases), Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital of Turin, Department of Clinical and Biological Sciences, University of Turin, 10154 T
  • Sinico RA; IRCCS Ospedale San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, 20132 Milan, Italy.
  • Bonelli G; Faculty of Medicine and Surgery, Università Vita-Salute San Raffaele, 20132 Milan, Italy.
  • Alberici F; Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas Research Hospital, 20072 Milan, Italy.
  • Mescia F; Renal Unit, Department of Medicine and Surgery, Università degli Studi di Milano Bicocca and ASST-Monza, 20900 Monza, Italy.
  • Moroni L; Renal Unit, Department of Medicine and Surgery, Università degli Studi di Milano Bicocca and ASST-Monza, 20900 Monza, Italy.
  • Tamborini F; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy.
  • Miraglia P; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy.
  • Bellocchi C; IRCCS Ospedale San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, 20132 Milan, Italy.
  • Beretta L; Faculty of Medicine and Surgery, Università Vita-Salute San Raffaele, 20132 Milan, Italy.
  • Roccatello D; Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico Milano, Divisione di Nefrologia e Dialisi, 20122 Milan, Italy.
  • Dagna L; Nephrology and Dialysis Unit & CMID (Center of Research of Immunopathology and Rare Diseases), Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital of Turin, Department of Clinical and Biological Sciences, University of Turin, 10154 T
  • Bozzolo E; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Referral Centre for Systemic Autoimmune Diseases, 20122 Milan, Italy.
  • Caporali R; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Referral Centre for Systemic Autoimmune Diseases, 20122 Milan, Italy.
Vaccines (Basel) ; 10(5)2022 Apr 22.
Article in English | MEDLINE | ID: covidwho-1875815
ABSTRACT
Vulnerable subjects, including systemic lupus erythematosus (SLE) patients, have been prioritised to receive anti-SARS-CoV-2 vaccines. Few data about the safety of these vaccines in SLE are available. The aim of our study is to investigate the safety of anti-SARS-CoV-2 vaccines in SLE. We included 452 SLE patients, referring to seven tertiary centres, who were immunised. A total of 119 (26%) reported side effects (SE) after the first and/or the second shot (the most frequent SE were fever, local reaction, fatigue, and arthralgia). Patients with constitutional symptoms and those on an immunosuppressive regimen (especially belimumab) showed more SE. In addition, 19 (4%) had a flare after the immunisation (flares classified by organ involvement six musculoskeletal with constitutional symptoms, four renal, three cardio-respiratory, three haematological, two mucocutaneous). None of the patients needed hospitalisation and none died. Moreover, 15 required a transient increase in corticosteroids and four were treated with steroid pulses. One patient required an additional rituximab course. Anti-dsDNA, moderate/high DAS before vaccine, and belimumab were found more frequently in patients with disease flare. Anti-SARS-CoV-2 vaccines are safe in SLE patients, and they should be recommended in these patients, as the potential benefits widely outweigh the risk of SE. Treatment adjustment might be considered with the aim of minimising SE risk and flare.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050663

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050663